Sarepta Therapeutics, Inc.
SRPT
$21.04
$0.572.78%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -179.95M | 196.89M | -447.51M | 159.05M | 33.61M |
| Total Depreciation and Amortization | 18.45M | 10.84M | 9.98M | 10.46M | 9.81M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 176.14M | 4.07M | 135.87M | 47.54M | 102.51M |
| Change in Net Operating Assets | -29.23M | 49.53M | -281.78M | -124.99M | -216.62M |
| Cash from Operations | -14.59M | 261.34M | -583.44M | 92.05M | -70.70M |
| Capital Expenditure | -22.93M | -31.80M | -43.65M | -38.08M | -37.26M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 255.33M | 64.01M | -247.53M | 802.20M | -91.56M |
| Cash from Investing | 232.40M | 32.21M | -291.18M | 764.12M | -128.83M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -123.94M | -304.00K | -3.21M | -68.00K | -- |
| Issuance of Common Stock | 21.21M | 1.50M | 15.68M | 3.71M | 13.76M |
| Repurchase of Common Stock | 0.00 | -25.01M | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -15.06M | -- | -- | 45.35M | -- |
| Cash from Financing | -117.79M | -23.82M | 12.47M | 48.99M | 13.76M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 100.03M | 269.73M | -862.14M | 905.16M | -185.77M |